Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.47 |
| ▸ | NMT1 | P30419 | 5/20 | 0.43 |
| ▸ | NMT2 | O60551 | 4/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 5/20 | 0.39 |
| ▸ | NPY1R | P25929 | 4/20 | 0.39 |
| ▸ | NPY2R | P49146 | 4/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593243 | 0.98 | SLC15A2 (0.43) | SLC15A2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL29435094 | 0.94 | SLC15A2 (0.45) | SLC15A2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL29461533 | 0.94 | SLC15A2 (0.51) | SLC15A2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL30372694 | 0.94 | SLC15A2 (0.51) | SLC15A2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL5598713 | 0.94 | SLC15A2 (0.51) | SLC15A2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL30713830 | 0.94 | SLC15A2 (0.51) | SLC15A2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL31717990 | 0.94 | SLC15A2 (0.51) | SLC15A2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL31106970 | 0.94 | SLC15A2 (0.51) | SLC15A2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL30373028 | 0.94 | SLC15A2 (0.51) | SLC15A2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL5598706 | 0.94 | SLC15A2 (0.51) | SLC15A2NMT1NMT2SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835609-B2 | Hydrogels for delivery of therapeutic compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-11-17 | — | — | US | disclosed |
| US-9937256-B2 | Hydrogels for delivery of therapeutic compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937256-B2 | Hydrogels for delivery of therapeutic compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160206741-A1 | HYDROGELS FOR DELIVERY OF THERAPEUTIC COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-07-21 | — | — | US | disclosed |
| US-20160206741-A1 | HYDROGELS FOR DELIVERY OF THERAPEUTIC COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835609-B2 | Hydrogels for delivery of therapeutic compounds | SI, VIP, DNPEP | SLC15A2 2775/4885NMT1 604/4885NMT2 834/4885 |
| US-20160206741-A1 | HYDROGELS FOR DELIVERY OF THERAPEUTIC COMPOUNDS | SI, VIP, DNPEP | SLC15A2 2775/4885NMT1 604/4885NMT2 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.